All In Biotech

Drug Trial Radar · NCT07778316

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants With Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-315)

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Sep 24, 2027

Study completion Jul 30, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

Conditions

  • Small Cell Lung Cancer

Interventions

  • TarlatamabDrug

    Administered via SC injection or IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve From Cycle 2 Day 1 to Day 15 (AUC C2D1-D15) of TarlatamabTime frame: From Cycle 2 Day 1 to Day 15 (each cycle is 28 days)
  2. Predose Concentration (Ctrough) of TarlatamabTime frame: On Cycle 2 Day 15 (each cycle is 28 days)

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Florida Health Cancer Center at Orlando Health

    Orlando, Florida · Recruiting

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • Oncology Hematology West PC

    Omaha, Nebraska · Recruiting

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

  • Beijing Chaoyang Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Tokyo Metropolitan Komagome Hospital

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Universitaetsspital Zuerich

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.